IDEAYA Biosciences announced Q4 and full year 2025 financial results, reporting collaboration revenue of $10.9 million in Q4 and net loss of $83.3 million, with cash of $1.05 billion as of December 31, 2025, expected to fund operations into 2030. Key clinical updates include 130 PFS events confirmed in OptimUM-02 trial with topline results expected by late March 2026.
Key takeaways
130 PFS events confirmed by BICR in Phase 2/3 OptimUM-02 trial of darovasertib + crizotinib in 1L HLA*A2-negative mUM; topline results expected last week of March 2026
Cash, cash equivalents, and marketable securities of $1.05 billion as of December 31, 2025; expected to fund operations into 2030
Q4 2025 collaboration revenue $10.9 million vs $7.0 million in Q4 2024; net loss $83.3 million vs $130.3 million
Full year 2025 net loss $113.7 million vs $274.5 million in 2024
GSK to terminate collaboration agreement and transfer IDE275 and IDE705 programs to IDEAYA
Darovasertib anticipated in three Phase 3 registrational trials in uveal melanoma by H1 2026